American Association for the Advancement of Science, Science Translational Medicine, 334(8), 2016
DOI: 10.1126/scitranslmed.aad3001
Full text: Download
JAK2 amplification decreases survival in triple-negative breast cancer but can be targeted with JAK2-specific inhibitors.